Stocks · News reference

HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21

Jul 20, 2026, 3:52 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 5:15 PMBenzinga Newsdesk
Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.
Read original at benzinga
OKUR
SEC EDGARAug 12, 2026, 10:22 PMSEC EDGAR
8-K filing — OnKure Therapeutics, Inc. (OKUR)
Filed: 2026-08-13 AccNo: 0001193125-26-347315 Size: 158 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgar
OKUR
BenzingaAug 4, 2026, 9:40 PMBenzinga Newsdesk
CORRECTION: OnKure Therapeutics Q2 EPS $(0.31) Beats $(0.54) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 41.51 percent. This is a 72.81 percent increase over losses of $(1.14) per share
Read original at benzinga
OKUR
BenzingaAug 4, 2026, 9:22 PMBenzinga Newsdesk
OnKure Therapeutics Announces Registration Of Up To $100M At-The-Market Offering Of Class A Common Stock Through Leerink Partners
https://www.sec.gov/Archives/edgar/data/1637715/000119312526332839/okur_424b5-20260804.htm
Read original at benzinga
OKUR